Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revive Therapeutics Ltd (CSE: RVV )

0.0250 -0.0050 (-16.67%)
Streaming Delayed Price Updated: 3:40 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revive Therapeutics Ltd

< Previous 1 2 Next >
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
First subject enrolled and initial top-line results expected in Q3-2023 
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Ltd. Closes $4.3 Million Offering
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Ltd. Expands Life Offering to Quebec
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market
Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to... 
Via FinancialNewsMedia
Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027
Via FinancialNewsMedia
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.